Clofarabine in adult acute leukemias: Clinical success and pharmacokinetics

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 8-9, 2004, Pages 1417-1423

  Cooper, Todd ^a   Kantarjian, Hagop ^a   Plunkett, William ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

AML; Chloro fluoro ara A; Clofarabine; Leukemia; Nucleoside analog; Pharmacology

Indexed keywords

CLADRIBINE; CLOFARABINE; DEOXYADENOSINE DERIVATIVE; FLUDARABINE;

ACUTE LEUKEMIA; ADULT; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA SYNTHESIS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG INFUSION; DRUG MECHANISM; HAND FOOT SYNDROME; HUMAN; INHIBITION KINETICS; LEUKEMIA CELL; LIVER DYSFUNCTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RASH; TREATMENT OUTCOME;

ADENINE NUCLEOTIDES; ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; ARABINONUCLEOSIDES; CLINICAL TRIALS; COHORT STUDIES; CYTARABINE; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LEUKEMIA, MYELOCYTIC, ACUTE; MODELS, CHEMICAL; MYELODYSPLASTIC SYNDROMES; NEOPLASM METASTASIS; NEOPLASMS; NUCLEOSIDES; TREATMENT OUTCOME;

ARA;

EID: 10344238593     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-200027650     Document Type: Conference Paper

References (15)

1. Montgomery, J.A.; Shortnacy-Fowler, A.T.; Clayton, S.D.; Riordan, J.M.; Secrist, J.A. Synthesis and Biologic Activity of 2′ fluoro-2-halo derivatives of 9-β-D-arabinofuranosyladenine. Biochem. Biophys. Res. Commun. 1983, 113, 35-43.
2. Parker, W.B.; Shaddix, S.C.; Chang, C.H.; White, E.L.; Rose, L.M.; Brockman, R.W.; Shortnacy, A.T.; Montgomery, J.A.; Secrist, J.A., III; Bennett, L.L., Jr. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res. 1991, 51, 2386.
3. Parker, W.B.; Shaddix, S.C.; Rose, L.M.; Waud, W.R.; Shewach, D.S.; Tiwari, K.N.; Secrist, J.A., III. Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl), 2-chloro-9-(2-deoxy-2- fluoro-β-D-ribofuranosyl)adenine, 2-chloro-9-(2-deoxy-2,2-difluoro-β- ribofuranosyl)adenine in CEM cells. Mol. Pharmacol. 1999, 55, 515-520.
4. Xie, K.C.; Plunkett, W. Metabolism and actions of 2-chloro-9-(2-deoxy-2- fluoro-β-D-arabinofuranosyl)adenine in human lymphoblastoid cells. Cancer Res. 1995, 55, 2847-2852.
5. Xie, K.C.; Plunkett, W. Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-D- arabinofuranosyl)adenine. Cancer Res. 1996, 56, 3030-3037.
6. Genini, D.; Budihardjo, I.; Plunkett, W.; Wang, X.; Carrera, C.J.; Cottam, H.B.; Carson, D.A.; Leoni, L.M. Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway. J. Biol. Chem. 2000, 27, 29-34.
7. Genini, D.; Adachi, S.; Chao, Q.; Rose, D.W.; Carrera, C.J.; Cottam, H.B.; Carson, D.A.; Leoni, L.M. Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. Blood 2000, 96, 3537-3543.
8. Kantarjian, H.M.; Gandhi, V.; Kozuch, P.; Faderl, S.; Giles, F.; Cortes, J.; O'Brien, S.; Ibrahim, N.; Khuri, F.; Du, M.; Rios, M.B.; Jeha, S.; McLaughlin, P.; Plunkett, W.; Keating, M. Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J. Clin. Oncol. 2003, 21, 1167-1173.
9. Kantarjian, H.M.; Gandhi, V.; Cortes, J.; Verstovsek, S.; Du, M.; Garcia-Manero, G.; Giles, F.; Faderl, S.; O'Brien, S.; Jeha, S.; Davis, J.; Shaked, Z.; Craig, A.; Keating, M.; Plunkett, W.; Freireich, E.J. Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia. Blood June 2003, (In Print);online.
10. Jeha, S.; Gandhi, V.; Chan, K.W.; McDonald, L.; Ramirez, I.; Madden, R.; Rytting, M.; Keating, M.; Plunkett, W.; Kantarjian, H. Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 2003. in press.
11. Gandhi, V.; Plunkett, W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res. 1988, 48, 329-334.
12. Gandhi, V.; Kemena, A.; Keating, M.J.; Plunkett, W. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res. 1992, 52 (4), 897-903.
13. Gandhi, V.; Estey, E.; Keating, M.J.; Plunkett, W. Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J. Clin. Oncol. 1993, 11, 116-124.
14. Cooper, T.; Nowak, B.; Gandhi, V. Biochemical modulation of cytarabine triphosphate by clofarabine. Proc. Am. Assoc. Cancer Res. 2003, 44, 142.
15. Faderl, S.; Gandhi, V.; Cortes, J.; Wierda, W.; O'Brien, S.; Keating, M.J.; Craig, A.; Kwari, M.; Plunkett, W.; Kantarjian, M. Clofarabine is active as a single agent and in combination with ara-C in patients with relapsed/refractory acute leukemias and high-risk myelodysplastic syndrome (MDS). Proc. Am. Soc. Clin. Oncol. 2003, 22, 586.